Cingulate Inc. Common Stock
Veridion Score
Composite trend over time
Why is CING moving today?
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CING.
CING insider activity
Cingulate Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $667K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-08 | 2026-02-13 | Hargroves Thomas Jeffrey | Insider | buy | $0.10 | 77,821 | 77,821 | $8K | SEC Form 4 |
| 2026-06-08 | 2026-02-13 | Hargroves Thomas Jeffrey | Insider | buy | $5.04 | 97,276 | 97,468 | $490K | SEC Form 4 |
| 2026-02-10 | 2026-02-06 | Werth Peter J. | Insider | buy | $0.10 | 15,564 | 15,564 | $2K | SEC Form 4 |
| 2026-02-10 | 2026-02-06 | Werth Peter J. | Insider | buy | $5.04 | 19,455 | 117,449 | $98K | SEC Form 4 |
| 2026-02-10 | 2026-02-06 | Callahan Jennifer L. | Insider | buy | $0.10 | 3,891 | 3,891 | $389 | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 5 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCING contract awards, year to date.
Public federal awards linked to this ticker.
CING lobbying filings, year to date.
Registered lobbying filings matched to Cingulate Inc. Common Stock.